According to a single-arm phase 2 clinical trial conducted by the University of Pittsburgh, UPMC Hillman Cancer Center and National Cancer Institute (NCI). Results published in Cancer Cellsupport the development of vidutolimod for the treatment of cutaneous melanoma and provide critical insights that could advance research into this drug for utilize in the treatment of […]
Scientists have developed a fresh drug that may show promise in treating Alzheimer’s disease because it blocks the build-up of tau protein and acts on two regions of the protein, preventing it from sticking together. The newest drug, RI-AG03, is a peptide inhibitor developed by a research team led by Lancaster University in collaboration with […]
Glioblastoma multiforme is an extremely aggressive brain tumor that is currently incurable. Oncologists can extend the life expectancy of patients with surgery, radiotherapy, chemotherapy, or surgical interventions. However, half of patients die within twelve months of diagnosis. Drugs that are effective against brain tumors are demanding to find because many cancer drugs often can’t cross […]
The antibody-drug conjugate (ADC) puxitatug samrotecan (AZD8205) demonstrated an adequate safety profile consistent with similar ADCs and initial efficacy in heavily pretreated patients with advanced or metastatic solid tumors, according to interim data shared today at the European Society for Medical Oncology (ESMO) 2024 Congress by investigators at The University of Texas MD Anderson Cancer […]
In a recent prospective observational cohort study published in eMedicineClinicalResearchers evaluated a modified total neoadjuvant treatment (TNT) regimen in patients with high-risk locally advanced rectal cancer (LARC) in Sweden. The modified TNT regimen was found to achieve similar complete response (CR) rates and lower neurotoxicity compared with the RAPIDO study, despite treating older patients with […]
